Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAdaptimmune Therapeutics plc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.17 | -$0.12 | -$0.15 |
| Q2 2024 | 1 | -$0.05 | -$0.04 | -$0.04 |
| Q3 2024 | 1 | -$0.01 | -$0.01 | -$0.01 |
| Q4 2024 | 3 | -$0.04 | -$0.01 | -$0.03 |
| Q1 2025 | 1 | -$0.13 | -$0.10 | -$0.12 |
| Q2 2025 | 1 | -$0.12 | -$0.09 | -$0.11 |
| Q3 2025 | 1 | -$0.10 | -$0.08 | -$0.10 |
| Q4 2025 | 1 | -$0.10 | -$0.07 | -$0.09 |
| Q1 2026 | 1 | -$0.12 | -$0.09 | -$0.11 |
| Q2 2026 | 1 | -$0.11 | -$0.08 | -$0.10 |
| Q3 2026 | 1 | -$0.09 | -$0.07 | -$0.08 |
| Q4 2026 | 1 | -$0.08 | -$0.06 | -$0.08 |
Adaptimmune Therapeutics plc Earnings Date And Information
Adaptimmune Therapeutics plc last posted its earnings results on Wednesday, November 13th, 2024. The company reported $-0.07 earnings per share for the quarter, topping analysts' consensus estimates of $-0.17 by $0.1. The company had revenue of 40.90 M for the quarter and had revenue of 60.28 M for the year. Adaptimmune Therapeutics plc has generated $-1 earnings per share over the last year ($-0.57 diluted earnings per share) and currently has a price-to-earnings ratio of -3.29. Adaptimmune Therapeutics plc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based on prior year's report dates.
Adaptimmune Therapeutics plc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q3 2024 | -$0.17 | -$0.07 | 0.1 | $18.96 M | $40.90 M |
| 08/12/2024 | Q2 2024 | -$0.07 | $0.27 | 0.34 | $40.47 M | $128.23 M |
| 05/15/2024 | Q1 2024 | -$0.16 | -$0.20 | -0.04 | $5.68 M | |
| 03/06/2024 | Q4 2023 | -$0.12 | -$0.21 | -0.09 | $233,009 | |
| 11/08/2023 | Q3 2023 | -$0.20 | -$0.20 | 0 | $7.97 M | $7.32 M |
| 08/09/2023 | Q2 2023 | -$0.17 | -$0.12 | 0.05 | $6.13 M | $5.13 M |
| 05/12/2023 | Q1 2023 | -$0.19 | $0.01 | 0.2 | $47.60 M | |
| 03/06/2023 | Q4 2022 | -$0.25 | -$0.18 | 0.07 | $11.03 M | |
| 11/08/2022 | Q3 2022 | -$0.28 | -$0.25 | 0.03 | $6.93 M | $7.01 M |
| 08/04/2022 | Q2 2022 | -$0.28 | -$0.28 | 0 | $6.57 M | $5.54 M |
| 05/09/2022 | Q1 2022 | -$0.26 | -$0.32 | -0.06 | $3.58 M | |
| 03/14/2022 | Q4 2021 | -$0.22 | -$0.25 | -0.03 | $1.42 M | |
| 11/04/2021 | Q3 2021 | -$0.27 | -$0.27 | 0 | $1.53 M | $1.20 M |
| 08/09/2021 | Q2 2021 | -$0.25 | -$0.25 | 0 | $1.40 M | $3.10 M |
| 05/06/2021 | Q1 2021 | -$0.25 | -$0.24 | 0.01 | $434,000 | |
| 02/25/2021 | Q4 2020 | -$0.23 | -$0.24 | -0.01 | $1.50 M | |
| 11/05/2020 | Q3 2020 | -$0.23 | -$0.23 | 0 | $1.02 M | $1.19 M |
| 08/06/2020 | Q2 2020 | -$0.24 | -$0.22 | 0.02 | $7.94 M | $502,000 |
| 05/28/2020 | Q1 2020 | -$0.23 | $761,000 | |||
| 02/27/2020 | Q4 2019 | -$0.33 | -$0.28 | 0.05 | $728,000 |
Adaptimmune Therapeutics plc Earnings: FAQ's
When is Adaptimmune Therapeutics plc's earnings date?
Adaptimmune Therapeutics plc has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates.
Did Adaptimmune Therapeutics plc beat their earnings estimates last
quarter?
In the previous quarter, Adaptimmune Therapeutics plc (:ADAP) reported $-0.07 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.17 by $0.1.
How can I listen to Adaptimmune Therapeutics plc's earnings conference
call?
The conference call for Adaptimmune Therapeutics plc's latest earnings report can be listened to online.
How can I read Adaptimmune Therapeutics plc's conference call transcript?
The conference call transcript for Adaptimmune Therapeutics plc's latest earnings report can be read online.
How much revenue does Adaptimmune Therapeutics plc generate each year?
Adaptimmune Therapeutics plc (:ADAP) has a recorded annual revenue of $60.28 M.
How much profit does Adaptimmune Therapeutics plc generate each year?
Adaptimmune Therapeutics plc (:ADAP) has a recorded net income of $60.28 M. Adaptimmune Therapeutics plc has generated $-0.57 earnings per share over the last four quarters.
What is Adaptimmune Therapeutics plc's price-to-earnings ratio?
Adaptimmune Therapeutics plc (:ADAP) has a price-to-earnings ratio of -3.29 and price/earnings-to-growth ratio is -0.09.